CORRECTION: Evogene Q2 EPS $(0.13) Beats $(0.27) Estimate, Sales $347.000K Beat $325.000K Estimate
Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.27) by 51.85 percent. This is a 74 percent increase over losses of $(0.50) per share from the same
Evogene lost less money than expected this quarter—their loss was smaller than what experts predicted. This means the company is improving how it spends money, which is a good sign to watch when checking if they're getting healthier.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.